Armata Pharmaceuticals Inc. is a biotechnology company dedicated to the development of innovative therapies to treat antibiotic-resistant infections. Operating in the healthcare sector, the company focuses on bacteriophage-based solutions, aiming to address the growing global issue of antimicrobial resistance. Armata Pharmaceuticals specializes in researching and developing treatments derived from natural phages, viruses that specifically target and eliminate bacteria, offering an alternative to traditional antibiotics. The company’s efforts are crucial in fields impacted by resistant bacterial strains, including healthcare-associated infections and chronic illnesses linked to bacterial biofilms. With its headquarters in the United States, Armata engages in collaborations with various research institutions and industry partners, emphasizing a scientific approach alongside cutting-edge technology. Armata Pharmaceuticals holds a significant position in the biopharmaceutical market, contributing to the advancement of precision medicine and public health innovations. Its dedication to addressing unmet medical needs positions it as a key player in the development of next-generation antimicrobial therapies. By exploring bacteriophage technology, Armata aims to provide targeted, effective alternatives that could revolutionize how infections are managed globally.